Krispy Kreme [DNUT] - Last Close: $12.45 The legendary donut maker is soaring after announcing an expansion to its national partnership with McDonald’s [MCD]. Customers will be able to buy Krispy Kreme donuts inside certain McDonald’s restaurants later this year, with a nationwide rollout expected by 2026.
Financial terms weren’t disclosed, but Krispy Kreme is rallying on the news. DNUT is up 20.3% on nearly 1 million shares traded.
My Take: DNUT is likely to sell a lot more donuts as a result of this deal. Shares have downtrended lately but this could be the catalyst for a breakout higher.
Stoke Therapeutics [STOK] - Last Close: $6.50
New clinical data supporting STK-001 as a treatment for Dravet Syndrome is lifting shares of Stoke Therapeutics in early premarket trading.
A Phase ½a trial showed the drug demonstrated “substantial and sustained reductions in convulsive seize frequency” and “median reductions of 85% at 3 months.”
The drug was also generally well tolerated, and the company plans to meet with regulatory agencies to discuss a clinical path forward.
STOK is up 80.7% on nearly 3 million shares traded.
My Take: STOK looks like it’s in a good spot, and this rally could help it breakthrough a key resistance point at around $8 per share.
OpGen [OPGN] - Last Close: $0.4750
OpGen is rallying after announcing a $3 million acquisition of its preferred stock by experienced private investor David Lazar.
Under the terms of the agreement, Lazar will acquire 3 million shares of Series E Convertible Preferred Stock at a price of $1 per share.
OPGN is up 60.0% on nearly 20 million shares traded.
My Take: David Lazar’s interest in this company could be a promising signal. Eventually, it could lead to a buyout. OPGN could be worth watching.
Check-Cap [CHEK] - Last Close: $1.97
Late Monday, Check-Cap announced its entrance into a business combination agreement with Nobul Al Corp.
Under the terms of the arrangement, the companies will combine into a public company headquartered in Toronto.
The companies are also planning to apply for listing on the NASDAQ and TSX, and both boards have agreed to the transaction.
CHEK is up 37.3% on nearly 7 million shares traded.
My Take: Details are scant on this deal, and CHEK’s chart doesn’t look very promising. Tread lightly here. Gainers ABVC Biopharma [ABVC] >> +49.5% Mesoblast [MESO] >> +31.8% Garden Stage [GSIW] >> +34.9% Decliners NeuBase Therapeutics [NBSE] >> (55.2%) Apptech [APCX] >> (39.4%) Murano Global [MRNO] >> (17.0%) McCormick & Company [MKC] ... AM TD Synnex [SNX] ... AM Waterdrop [WDH] ... AM Movado [MOV] ... AM Direct Digital [DRCT] ... AM GameStop [GME] ... PM Concentrix [CNXC] ... PM nCino [NCNO] ... PM Progress Software [PRGS] ... PM Forge Global Holdings [FRGE] ... PM Durable-goods orders [Feb] ... 8:30a Durable-goods minus transportation [Feb] ... 8:30a S&P Case-Shiller home price index (20 cities) [Jan] ... 9:00a Consumer confidence [Mar] ... 10:00a |